Metastatic pancreatic cancer has resisted nearly every advance in oncology of the past two decades. Among 500 patients with previously treated metastatic pancreatic cancer, daraxonrasib extended median overall survival to 13.2 months compared with 6.7 months on standard chemotherapy. On May 1, 2026, the FDA issued a letter permitting an expanded access treatment protocol. Pancreatic cancer is the third-leading cause of cancer death in the United States and kills nearly 53,000 people a year. The confirmed finding is that daraxonrasib nearly doubled median survival in previously treated metastatic pancreatic cancer.